Replies to post #111419 on Anavex Life Sciences Corp (AVXL)

[nobrainerstocks]

I just managed to contact the granddaughter of one patient who was on the Anavex trial and who was featured in an Australian TV segment a couple of years ago. This is what she said when I asked how he was doing:

'My grandfather stopped the Anavex in February 2016. It was great while he was on it and helped slow the progression of his Alzheimer's, he just became too frail in the end. Unfortunately my grandfather passed away in May this year. Hope this was helpful.'

So you are right William, besides having Alzheimer's some of these people are just old and may suffer from other ailments that they succumb to.

[F1ash]

The patient population is made up of feeble geriatrics. Some probably just died from complications associated with old age and poorer health then others.

There don't appear to be any indications of safety issues with A2-73. The dropout rate in this frail population is actually pretty low. Very encouraging for probable long term safety imho.

Here is the actual data from dropouts and the reason they dropped out.


"Completed PART A (n=30)"


Discontinued (n=2)

• Consent withdrawn
• AE: Delirium; Grade 2



"Completed PART B 6 months open- label extension (n=27)"

Discontinued (n=3)

• Consent withdrawn

• AE: Dizziness; Grade 1
AE: Confusion, disorientation,
lethargy; Grade 1



"Completed PART B 12 months open- label extension (n=25)"


Discontinued (n=2)

• Consent withdrawn
• Lost to follow up


See slide 22 which appears to indicate that the above dropouts are only for the first 54 weeks and not from the Part B ( 52 week extension of the extension). Probably very confusing to most investors imho.

http://wsw.com/webcast/jeff105/avxl/